Search
Search your stock
Analysis
Pfizer Inc. (PFE)
Pfizer Inc. (PFE)
Ranking:
Buy
Implies positive momentum
Stock Name: Pfizer Inc.
Symbol: PFE
Market Cap: $140.54B
Industry: Drug Manufacturers - General
Sector: Healthcare
Website: https://www.pfizer.com
About Pfizer Inc.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands Please visit their website for more information.

Overview:
Last Close: $24.8
52 Week: $24.17-$30.90
MVA50: 27.81
MVA200: 28.27
RSI: 30.78
Buy/Sell*: 17.25
1-Month change: -15.92%
3-Month change: -13.26%
*Proprietary Buy Sell Volume Indicator
Price Chart For PFE
Financial Parameters Most Recent Quarter: (2024-Q3),2024-09-29
Revenue: $17.70B
Revenue Growth (YOY): 33.78%
Profit (% of Rev): 70.27%
Income (% of Rev): 25.22%
Income Growth (YOY): -286.51%
Operating Income: $5.29B
Operating Cash Flow: $6.71B
Operating Cash Flow Growth (YoY): 94.27%
Annual Dividend Yield: 1.45%
Total Assets: $219.48B
Total Liabilities: $126.92B
Cash & Equivalent: $1.09B
Total Debt: $66.62B
Debt/Equity: 0.73
Quick Ratio: 0.73
Current Ratio: 1.00
Price/Book: 1.78
Price/Earnings: 9.18
EBITDA: $7.25B
EPS: 0.79
Our Approach

Our proprietary analysis employs a weighted average approach integrating both functional and technical parameters, tailored to the sector, industry, and microeconomic factors. This methodology assigns dynamic weights to the parameters, with a focus on recent trends, ensuring a nuanced evaluation for informed investment decisions. Considering all the above parameters, in addition to some of the derived parameters of the stock in conjunction with its sector and macroeconomic conditions, our proprietary Weighted Average AI model gives a rank of Buy.

TheoryofStocks is not registered as an investment advisor with any regulatory authority. The information provided on this Website is for educational purposes only and should not be construed as financial or investment advice. By continuing to use this site, you are agreeing to the Terms of Use and Privacy Policy. Please read our Disclaimer.

Contact @ support@theoryofstocks.com

© 2024 Stock Articles. All rights reserved.

This site uses cookies to ensure the best experience. By continuing to use this site, you agree to their use.

Click here for Cookie Policy